A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/48 (2006.01) A61K 9/70 (2006.01) A61M 37/00 (2006.01) A61P 25/00 (2006.01)
Patent
CA 2502142
The invention concerns a transdermal therapeutic system containing ergoline derivatives, preferably lisuride, with a stabilized ergoline compound. Stabilization of the oxidation sensitive ergoline combination is done through a combination of at least one fat- soluble, radical-trapping antioxidant, preferably Di-tert.-butylmethylphenols, Di-tert.- butylmetoxyphenols, tocopherols or ubichinones and a basic polymer. Use of a transdermal therapeutic system (TTS) comprising a pharmaceutical layer containing at least one matrix having an active ingredient and/or an active ingredient reservoir; a diffusion barrier that is permeable to said active ingredient and arranged on the skin side of the active ingredient reservoir; and an ergoline derivative or salt thereof as an active ingredient for producing an agent for obtaining and maintaining the circadian rhythm under dopamine therapy. The invention relates to the use of a transdermal therapeutic system (TTS) comprising a medicinal layer, which contains at least one matrix comprising an active ingredient and/or an active ingredient reservoir and a diffusion barrier situated on the skin side of the active ingredient reservoir and permeable to active ingredients, in addition to, an ergoline-derivative or physiologically compatible salt with an acid thereof, as an active ingredient, for producing a means for treating the Restless Leg Syndrome and Periodic Limb Movement Disorder. The invention relates to the use of a dopamine agonist in the form of an agent consisting of at least two spatially discrete compositions, of which one is a transdermal therapeutic system (TTS) containing the dopaminergic agent and another one or more are preparations for oral and/or parenteral application containing that same dopaminergic agent for the treatment of dopaminergically treatable diseases with the following elements: a) the TTS is continuously applied, b) within the duration of application in a) the composition for oral or parenteral dosage is administered.
Bostedt Katalin Tisa
Engfer Adalbert
Gunther Clemens
Horowski Reinhard
Schenk Dirk
Axxonis Pharma Ag
Moffat & Co.
Neurobiotec Gmbh
LandOfFree
Transdermal therapeutic systems does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transdermal therapeutic systems, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transdermal therapeutic systems will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1593603